LP
MIRM icon

LMR Partners’s Mirum Pharmaceuticals MIRM Stock Holding History

LMR Partners’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,068
Closed -$194K – 577
2020
Q3 		$194K Hold
10,068
– – ﹤0.01% 346
2020
Q2 		$196K Buy
+10,068
New +$168K ﹤0.01% 490

Other funds holding MIRM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

LMR Partners's MIRM Position: Q4 2020 in Review

LMR Partners sold out of Mirum Pharmaceuticals (MIRM) in Q4 2020, closing a stake of 10,068 shares — an estimated $194K sold.

LMR Partners first reported a position in MIRM in Q2 2020 and held it in 2 quarters. The position peaked at $196K in Q2 2020. 72 funds tracked by Wall St. Rank hold MIRM as of Q4 2020.

  • LMR Partners reported no remaining Mirum Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • LMR Partners sold 10,068 Mirum Pharmaceuticals shares in Q4 2020, an estimated $194K.
  • LMR Partners first reported a position in Mirum Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • LMR Partners's Mirum Pharmaceuticals position peaked at $196K in Q2 2020.
  • 72 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q4 2020.

Based on LMR Partners's 13F filing for Q4 2020, filed 16 Feb 2021.